Wednesday, 4 July 2012

Questions (231)

Dan Neville


234 Deputy Dan Neville asked the Minister for Health if the Vertex created kayldeco drug for people with cystic fibrosis, with the G155D mutation, is available through the health services under the long-term illness scheme. [32540/12]

View answer

Written answers (Question to Minister for Health)

Ivacaftor (Kalydeco) received a positive opinion from the Committee for Medicinal Products for Human Use at EU level in May 2012. Marketing authorisation issued by the EU Commission is anticipated in due course. Should the manufacturers make an application for inclusion of the product on the GMS and community drugs schemes, that application shall be considered in accordance with the relevant criteria.